Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy
Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy
复制标题
DOI：
10.1016/j.breast.2010.11.004
复制
发表时间：
2011-06-01
期刊：
影响因子：
3.9
通讯作者：
Cheung, Kwol Leung
中科院分区：
文献类型：
--
作者：
Morgan, David A. L.;Refalo, Nicholas A.;Cheung, Kwol Leung
目的：雌激素受体（ER）阳性已被证明是乳腺癌患者内分泌治疗反应的预测因素。乳腺手术后，根据各种参数（包括诺丁汉预后指数（NPI）、绝经状态和ER状态）分配辅助治疗。肿瘤福尔斯在相同NPI范围内的患者可根据ER状态接受不同的辅助治疗。我们研究的目的是评估ER阳性的程度，通过免疫组化H评分测量，（参见“引言”部分中的定义）和ER染色细胞的百分比）对总生存期（OS）和无病生存期（DFS）有影响，以及这是否可用于帮助确定辅助治疗。对563例绝经后患者进行了回顾性研究，这些患者在手术切除经组织学证实的ER阳性乳腺癌后接受了他莫昔芬辅助治疗，而没有接受化疗。使用OS和DFS在10年的period.Results的影响，H-评分和ER染色的细胞百分比进行了评估：患者分为4组，根据ER H-评分，即那些得分200。H评分高于200的患者10年生存率为84%，H评分100-200的患者为67%，H评分50-100的患者为71%，H评分低于50的患者为41%（p
Aims: Oestrogen receptor (ER) positivity has been shown to be a predictive factor for response to endocrine treatment in breast cancer patients. Following breast surgery, adjuvant treatment is allocated according to various parameters (including Nottingham Prognostic Index (NPI), menopausal status and ER status). Patients whose cancer falls in the same NPI range may receive different adjuvant treatment according to ER status. The aim of our study is to assess whether the degree of ER-positivity, as measured immuno-histochemically by H-score (see definition in "Introduction" section) and percentage of ER-stained cells) has an influence on overall survival (OS) and disease-free survival (DFS) and whether this could be used to help determine adjuvant treatment.Materials and methods: A review was undertaken of 563 post-menopausal patients receiving adjuvant tamoxifen and no chemotherapy following surgical resection of histologically proven ER-positive breast cancer. The impact of both H-score and percentage of cells staining for ER was assessed using OS and DFS over a 10-year period.Results: Patients were stratified into 4 groups according to ER H-score, namely those scoring 200. Ten-year survival was 84% for H-score above 200, 67% for H-score 100-200, 71% for H-score 50-100 and 41% for H-score less than 50 (p